Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting
08.12.2021 - JSP191 is well tolerated with no treatment-related adverse events in dose-escalation studySingle-agent conditioning with JSP191 is associated with engraftment, immune reconstitution, and clinical benefit REDWOOD CITY, Calif., Dec. 08, 2021 ... Seite 1
Single Agent Conditioning Regimen Results Successful Engraftment Donor Myeloid Chimerism Severe Combined Immunodeficiency Conditioning Regimens Acute Toxicities
Source: wallstreet-online.de